Showing results (101-110 of 3,702) with videos related to
Sort By:
Pageof 371
Pharmacology & Therapeutics|October 6, 2021
Biologically active lipids in the regulation of lymphangiogenesis in disease statesMasataka Majima, Kanako Hosono, Yoshiya Ito, et al.Pharmacology & Therapeutics|October 9, 2021
The new fate of internalized membrane receptors: Internalized activationWenjing Wang, Jingwei Bian, Yang Sun, et al.Pharmacology & Therapeutics|March 19, 2022
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acidM John Chapman, Jose L Zamorano, Klaus G ParhoferPharmacology & Therapeutics|February 21, 2022
Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugsAntje-Christine Walz, Arthur J Van De Vyver, Li Yu, et al.Pharmacology & Therapeutics|April 3, 2022
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular diseaseTao-Xiang Chen, Yuan-Teng Fan, Bi-Wen PengPharmacology & Therapeutics|April 3, 2022
Inflammation and oxidative stress as mediators of the impacts of environmental exposures on human pregnancy: Evidence from oxylipinsBarrett M Welch, Erin E McNell, Matthew L Edin, et al.Pharmacology & Therapeutics|March 9, 2022
Treatment of chronic cough: P2X3 receptor antagonists and beyondDominic L Sykes, Mengru Zhang, Alyn H MoricePharmacology & Therapeutics|March 5, 2022
Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseasesJ Zeller, B Bogner, J D McFadyen, et al.Pharmacology & Therapeutics|May 4, 2019
Targeting opioid dysregulation in depression for the development of novel therapeuticsCaroline A Browne, Irwin LuckiPharmacology & Therapeutics|March 2, 1999
New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's diseaseV Bonifati, G MecoPageof 371